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Abstract
Purpose: Currently, no genomic signature exists to distinguish men most likely to progress on
adjuvant androgen deprivation therapy (ADT) after radical prostatectomy for high-risk prostate
cancer. Here we develop and validate a gene expression signature to predict response to
postoperative ADT.

Author Manuscript

Experimental Design: A training set consisting of 284 radical prostatectomy patients was
established after 1:1 propensity score matching metastasis between adjuvant-ADT (a-ADT)treated and no ADT–treated groups. An ADT Response Signature (ADT-RS) was identified from
neuroendocrine and AR signaling–related genes. Two independent cohorts were used to form three
separate data sets for validation (set I, n = 232; set II, n = 435; set III, n = 612). The primary
endpoint of the analysis was postoperative metastasis.
Results: Increases in ADT-RS score were associated with a reduction in risk of metastasis only
in a-ADT patients. On multivariable analysis, ADT-RS by ADT treatment interaction term
remained associated withmetastasis in both validation sets (set I: HR = 0.18, Pinteraction = 0.009;
set II: HR = 0.25, Pinteraction = 0.019). In a matched validation set III, patients with Low ADT-RS
scores had similar 10-yearmetastasis rates in the a-ADT and no-ADTgroups (30.1%vs. 31.0%, P =
0.989).AmongHigh ADT-RS patients, 10-year metastasis rates were significantly lower for a-ADT
versus no-ADT patients (9.4% vs. 29.2%, P = 0.021). The marginal ADT-RS by ADT interaction
remained significant in the matched dataset (Pinteraction = 0.035).

Author Manuscript

Conclusions: Patients with High ADT-RS benefited from a-ADT. In combination with
prognostic risk factors, use of ADT-RS may thus allow for identification of ADT-responsive
tumors that may benefit most from early androgen blockade after radical prostatectomy. We
discovered a gene signature that when present in primary prostate tumors may be useful to predict
patients who may respond to early ADT after surgery.

Introduction

Author Manuscript

Androgen deprivation therapy (ADT) has served as the foundation for advanced prostate
cancer management since its discovery by Huggins and Hodges in 1941 (1). In fact, in the
United States, approximately half of all prostate cancer patients will receive a course of
ADT at some point during treatment (2). In the primary radiotherapy setting, a large body of
evidence supports the radiosensitizing properties of adjuvant ADT and a resultant overall
survival benefit (3). Similarly, in men with lymph node–positive disease after radical
prostatectomy, adjuvant ADT has demonstrated a survival benefit (4). Furthermore, large
retrospective series have also suggested improved cancer specific mortality with adjuvant
ADT in the presence of seminal vesicle invasion on surgical pathology (5). Indeed, the
adjuvant ADT arm of the SWOG S9921 trial of high-risk prostate cancer treated with radical
prostatectomy demonstrated a 92% 5-year biochemical recurrence-free survival (6).
Furthermore, several institutions have published favorable results with adjuvant ADT after
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radical prostatectomy for high-risk prostate cancer (7–9). In fact, an analysis of SEERMedicare data found that 23% of high-risk prostate cancer patient’s undergoing radical
prostatectomy received adjuvant ADT (10). Thus, while the majority of radical
prostatectomy patients do not receive adjuvant ADT, there are a significant number of highrisk prostate cancer patients receiving adjuvant ADT in the United States after radical
prostatectomy.

Author Manuscript

Nevertheless, despite its potential benefits, ADT has been associated with cardiovascular,
thrombotic, and cognitive side-effects in addition to its detrimental impact on quality of life
(11). Thus, it is vital to identify the subset of patients who are likely to receive no benefit
from ADT to not only minimize ADT-associated morbidity but also enable early transition
to other therapeutic options. Unfortunately, progression during and after adjuvant ADT for
clinically localized high-risk disease has been understudied, and investigations have
identified only a limited number of clinical predictors in this setting (12).
Herein, we employed multi-institutional radical prostatectomy cohorts to develop and
validate the first genomic signature (ADT response signature) predicting progression after
adjuvant ADT. The biologic rationale for the ADT-RS stems from the observation that
neuroendocrine prostate cancer (NEPCa) has higher rates of ADT resistance than
nonneuroendocrine histology and neuroen-docrine differentiation is highly correlated with
castration-resistant disease (13). We reasoned that a score created from gene expression
patterns of NEPCa (including NE differentiation, AR signaling, cell proliferation) may serve
as an early marker of androgen resistance for primary prostate tumors in the localized
disease setting.

Author Manuscript

Materials and Methods
Study design

Author Manuscript

Expression profiles for 1,212 patients were retrieved from Decipher GRID database
(NCT02609269), from three previously published studies of the Decipher test in men with
adverse pathology and clinical findings after radical prostatectomy (14–16). The training
cohort (Mayo Clinic I, n = 545 all Caucasian) is a case–control study. It was stratified into
those who received adjuvant androgen deprivation therapy within 1 year of radical
prostatectomy and prior to PSA recurrence (a-ADT) and those who did not receive adjuvant
ADT or received ADT after PSA recurrence or metastasis (no ADT). During the study
period, institutional practice at Mayo Clinic administration of a-ADT was generally intended
to be lifelong although it is uncertain whether patients discontinued treatment after a period
of ADT as described previously (17). a-ADT and no ADT patients were then matched using
propensity scores on pathologic features (preoperative PSA, pathologic Gleason score,
extraprostatic extension, seminal vesicle invasion) in a 1-to-1 ratio to define a matched
training set of 284 patients that was well-balanced across these variables including adjuvant
radiotherapy (Fig. 1; Table 1). Two independent cohorts, with case–cohort design, were used
to form three separate datasets for validation. Validation set I consisted of 232 Caucasian
men treated with radical prostatectomy at Mayo Clinic (MC) between 2001 and 2006 from a
previously reported case–cohort study. The sampling fraction for the MC cohort was 20%
(15). Validation set I included high-risk men treated with radical prostatectomy at MC and as
Clin Cancer Res. Author manuscript; available in PMC 2019 May 13.
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per institutional practice during the period of study, adjuvant ADT (± external beam
radiotherapy) was commonly administered to men with high Gleason scores and seminal
vesicle invasion (SVI) or those harboring lymph node invasion (LNI). Validation set II (n =
435) combined all patients from Validation set I with a subset of a second case– cohort
designed study of 260 men (21 African Americans, 235 Caucasian, 4 other races) treated
with radical prostatectomy between 2001 and 2009 at Johns Hopkins (JHU). The sampling
fraction for the JHU cohort was 35% (16). The JHU cohort included intermediate-high risk
men treated with radical prosta-tectomy that per institutional practice during the period of
study, received no adjuvant or salvage (i.e., upon PSA rise) therapy prior to metastatic onset
(“natural history cohort”). To properly analyze the data using Cox regression for case–cohort
studies, the JHU case–cohort study was modified by resampling the subcohort to match the
sampling fraction of the MC case-cohort study (18). Using the upweighted Validation Set II
(n = 1479), Validation set III used 1:1 propensity scores (19) to clinically match a-ADT to
no ADT patients, yielding 612 patients for analysis (Fig. 1; Table 1).
RNA extraction and data preprocessing
Specimen selection and processing and data normalization has been described previously
(16).
Feature selection and ADT response signature (ADT-RS) development
Asystematic literature review identified 1,632 genes extracted from studies investigating the
neuroendocrine differentiation, castration resistance models, and resistance to ADT
(Supplementary Table S1). This list also included several genes involved in AR signaling
and cell proliferation. This list was further filtered using a two-step filtering procedure:

Author Manuscript

i.

Feature ranking: 1,632 features were independently fit using a generalized linear
model (GLM) with logit link that incorporated an interaction between ADT
treatment status and the expression of each individual feature while adjusting for
confounding variables. Then, the features were ranked on the basis of their
Pinteraction (univariate feature ranking).

ii.

Model training: Using the first “n” number of features from this ranked list (the
number of “n” features will be optimized using leave-one-patient-out-crossvalidation LOOCV), a GLM was fit using ADT interaction with the “n” features
(Multivariable model training).

Author Manuscript

In our approach, LOOCV was performed on the training set to discover the optimal set of
features “n”. Beginning with three features (n = 3), the highest ranked three features were
used to train the model and calculate the cross-validated AUC. This process was repeated
with increasing number of features to train and calculate the cross-validated AUC. In each
iteration of LOOCV, the trained model was a logit model for which the optimal parameter
“lambda” was identified using the “cv.glmnet” function with 10-fold cross-validation, elastic
net mixing parameter set to one, and mean squared error as the optimization metric. This
optimization procedure was truncated at 100 features because there was no improvement in
the cross-validated AUC.
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The set of genes that produced the highest cross-validated AUC among ADT-treated patients
was used in training the final and locked model. The ADT-RS score for a given patient is
calculated by taking the difference between risk given ADT treatment and risk given no
ADT-treatment and has values that range from 1 and 1 (20). ADT-RS scores were scaled so
that higher scores (closer to 1) were associated with benefit from adjuvant ADT.
Statistical analysis

Author Manuscript

The primary endpoint of the analysis was metastatic onset following surgery (i.e., positive
bone and/or CT scans). Event times were defined as time from radical prostatectomy to
metas-tases or date of last follow up. Prognostic performance of genomic risk models was
assessed using the survival c-index (21) with bootstrapped 95% confidence intervals. For
purposes of comparisons with established prognostic models, ADT-RS scores were
multiplied by a factor of 1 so that higher scores reflect a higher risk of metastasis. Validation
of the response-predictive capability of the model was conducted using univariable and
multivariable Cox regression for case–cohort designs (18) to estimate the conditional effect
of biomarker by treatment interaction (22). Clinicopathologic variables that were adjusted
for in the multivariable analysis (MVA) included treating institution, preoperative PSA (log2
transformed), pathologic Gleason score (≥4+3 vs. ≤3+4), extraprostatic extension (EPE),
SVI, margin status (SM), LNI, and adjuvant radiotherapy (ART) defined as radiotherapy
within 12 months of radical prostatectomy. In addition, a matched analysis interrogating the
marginal interaction effect (22) was performed for comparison with the unmatched MVA. aADT were matched to no ADT patients in a one-to-one ratio, with replacement, on
clinicopathologic variables using the MatchIt package in R. Cumulative incidence curves for
metastasis were generated for a-ADT and no ADT groups within subsets of patients with
low and high predictive model scores using Fine–Gray competing risks analysis (23).
Statistical inference was conducted using a weighted version of the log-rank test (24). A Cox
regression model was fit to the matched Validation set III where the data were weighted by
the number of times a patient was selected and a robust variance (25) calculated for
statistical inference to account for the reweighting process. Decipher, mCCP (26) (the
microarray version of the cell-cycle progression signature created by taking the mean of the
31 CCP genes), and the ADT-RS were each categorized objectively based on their median
scores. Statistical analyses were performed in R v3.2.2, and all tests were performed at the
5% significance level.

Author Manuscript
Results

Development of ADT-RS

Author Manuscript

A radical prostatectomy cohort of 545 men with long-term follow up (median 16.9 years)
and available genome-wide expression profiles was used to derive a matched set of a-ADT
and no ADT patients (n = 284), which was used to train the ADT-RS model. Feature
selection was conducted on a curated list of 1,632 genes related to NEPCa, cell proliferation,
AR signaling, and castration resistance from a literature review (Supplementary Table S1).
Genes (n = 84,) with a significant interaction with ADT treatment were used to train the
model using a generalized linear model (Fig. 1). Only 49 genes had a nonzero coefficient
(Supplementary Table S2) and were contributing to the final score. The ADT-RS model has
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score values ranging from 1 to 1 where 1 is high response to ADT upon treatment (lower
likelihood of metastasis post-ADT) and −1 is lower response (higher likelihood of metastasis
post-ADT). We used the median score of 0.36 as a cut-off point to categorize patients into
either low ADT-RS or high ADT-RS. The cross-validated AUC among a-ADT patients in
the training cohort was 0.84.
On the basis of analyzing the biological function of the genes’ interactome, we found the
ADT-RS genes to be related to key signaling pathways including NOTCH, WNT β-catenin,
TNF-α, insulin, and chemokine signaling (Supplementary Fig. S1). In particular, the REST
and EZH2 genes were highly connected nodes in the functional network. SOX2 and
NANOG were identified as key transcription factors in enrichment analysis (P = 0.01).
Biological process over-representation analysis found cell-cycle activity, DNA repair,
chromatin modification, and immune response as the key gene ontologies in ADT-RS.

Author Manuscript

Clinical characteristics of validation sets

Author Manuscript

With a median follow up of 7 years among censored patients, 50% and 18% of men from
Validation set I developed metastasis in the a-ADT (n = 102) and no-ADT (n = 130) groups,
respectively. Fifty-eight percent of patients had a Gleason score ≥ 4+3 and 14% had lymph
node–positive disease (Table 1). In Validation set II, 102 patients were in the a-ADT group
and 64% of patients had a Gleason score ≥ 4+3 and 19% lymph node– positive disease
(Table 1). A total of 174 patients developed metastasis during study follow up with a median
7.9 years of follow up for censored patients. In the validation cohorts, among the treated and
metastasized patients, four patients received adjuvant ADT treatment within a month of
clinical metastasis as evidenced by imaging and one patient received ADT within 4 months
of clinical metastasis. In matched Validation set III, clinicopathologic variables including
Gleason score (P = 0.18) were balanced, but not the administration of adjuvant radiotherapy,
which remained substantially different across treatment arms (P < 0.001; Supplementary
Table S3).
Analysis of ADT-RS in validation sets I and II

Author Manuscript

In the validation sets, ADT-RS scores ranged from 0.92 to 0.97 (Fig. 2). ADT-RS had
survival c-indices at 5 years postsurgery of 0.63 in both Validation sets I (95% CI: 0.54–
0.70; Supplementary Table S4) and II (95% CI: 0.58–0.67), suggesting that independent of
its interaction with ADT the ADT-RS score itself had a weak prognostic capability.
However, the conditional interaction effect between ADT-RS and ADT treatment was
significant in multivariable Cox regression for both Validation sets I (HR = 0.18; Pinteraction
= 0.009) and II (HR = 0.25; Pinteraction = 0.019; Table 2). In other words, patients with higher
ADT-RS score had lower metastasis rates with adjuvant ADT as compared with men with
lower ADT-RS who also received this treatment. The only other significant variable in the
multivariable model for Validation set I was pathologic Gleason score (HR = 3.57; P =
0.001). In Validation set II, pathologic Gleason, seminal vesicle invasion, positive margins,
and lymph node positivity were also significantly associated with risk of metastasis.
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ADT-RS scores among the matched validation cohort were dichotomized using the median
score of 0.36 obtained from Validation set II as a cut-off point to categorize patients into
either Low ADT-RS or High ADT-RS. In the matched Validation set III, patients with low
ADT-RS scores had similar incidence rates of metastasis in both treated (31%) and untreated
arms (31.3%; Fig. 3A and B). In contrast, as judged by their metastatic outcomes among
men with high ADT-RS scores, a-ADT patients had a significant benefit with treatment
compared with patients with no treatment where the incidence rates were 9.4% and 29.2%,
respectively (P = 0.02; Fig. 3C). The marginal ADT-RS by ADT interaction effect was
statistically significant with a P value of 0.035 (Supplementary Table S5) and consistent
with the case– cohort validation sets suggesting ADT-RS is predictive of treatment-response
from ADT.

Author Manuscript

While the ADT-RS, Decipher, and cell-cycle genes genomic risk models each exhibited
varying but significant prognostic signal in discriminating metastatic risk across all three
validation sets (Supplementary Table S4), Decipher and cell-cycle genes did not predict
response to ADT (Fig. 4). Indeed, the marginal interaction effects for both risk models were
not significant (Decipher: HR = 1.61, P = 0.171; cell-cycle genes: HR = 1.40, P = 0.251;
Supplementary Table S5), illustrating what appear to be purely prognostic signatures
compared with the one that is both prognostic and predictive in ADT-RS.

Discussion

Author Manuscript

In this study, we leveraged historically different institutional practices related to the timing
of postoperative therapy between Mayo Clinic and Johns Hopkins to developed an 84-gene
ADT-response signature. We then validated it in radical prostatectomy cohorts from tertiary
referral centers using multivariable Cox regression analysis. At MC, a-ADT was commonly
administered to men with high-risk disease (e.g., SVI with high Gleason scores or LNI),
whereas at JHU no therapy of any kind was administered prior to metastatic onset (“natural
history cohort”). We observed that the HRs for metastasis of the ADT-RS-ADT interaction
term were 0.18 (Pinteraction = 0.009) and 0.25 (Pinteraction = 0.019) in the two validation sets,
respectively. In the matched Validation set III, ADT-RS was associated with reduced 10-year
metastasis in the a-ADT arm, but not in the no-ADT arm, supporting ADT-RS score is predictive of progression with adjuvant ADT. Taken together, these findings support that in
localized prostate cancer, an ADT-resistant phenotype (Low ADT-RS) and an ADT-sensitive
phe-notype (High ADT-RS) can be detected from gene expression analysis of radical
prostatectomy tissue.

Author Manuscript

To gain functional insights on the 84 genes, we extracted first-degree gene partners of ADTRS from human protein networks (27, 28) and conducted transcription factor enrichment
analysis using EnrichR online tool. The 84 genes retained in ADT-RS encompassed several
biologically relevant pathways that may explain the androgen-resistant phenotype
(Supplementary Fig. S1). For instance, REST has been associated with castration resistance
and neuroendocrine differentiation due to aberrant splicing patterns (29, 30). Similarly,
EZH2 was found to be the transcriptional mechanism for N-Myc associated neuroendocrine
differentiation (31). An earlier study showed that SOX2 is an AR-regulated genes that
Clin Cancer Res. Author manuscript; available in PMC 2019 May 13.
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promotes castration resistance (32). Recent investigation by Mu and colleagues (33) found
that inhibiting SOX2 could reverse neuroendocrine differentiation, and 8 genes in the ADTRS were regulated by SOX2. Thus, many of the genes in the ADT-RS have strong biologic
mechanisms to support their relevance to androgen resistance.

Author Manuscript
Author Manuscript

It is critical to distinguish a “predictive” score from a “prognostic” score at this juncture.
The importance of this distinction goes beyond nomenclature, as a predictive score for ADT
response has significant potential to influence clinical practice. Current guidelines
recommend adjuvant ADT after radical prostatectomy only if there is lymph node
involvement (34). However, there are large retrospective (5) and prospective (6) series
suggesting a benefit to adjuvant ADT in the high-risk pN0 setting. ADT-RScould be used to
identify these patients who are most likely to benefit from adjuvant ADT, thereby potentially
changing the current paradigm of adjuvant ADT. Furthermore, for patients who are not
likely to benefit from ADT, ADT-RS may enable triage of these patients to trials of other
therapeutic modalities while preventing the side effects of unnecessary ADT. This holds the
potential to change the paradigm of adjuvant ADT delivery after radical prostatectomy for
high risk prostate cancer. Recently Zhao and colleagues, reported on the application of the
PAM50 breast cancer classifier in prostate cancer and found that while the Luminal B
subtype had the worst prognosis (compared with Luminal A and Basal) they had better
survival with adjuvant hormones. We have analyzed ADT-RS scores in the context of
PAM50 subtypes for 5,239 radical prostatectomy patients and found that Luminal B subtype
is enriched with high ADT-RS scores (P = 0.0001; Supplementary Fig. S2). While, the genes
used for ADT-RS scores and PAM50 do not overlap, these results suggest that the ADT-RS
model scores and PAM50 subtypes are picking up similar tumor biology with clinical
implications for use of ADT. Ongoing studies led by investigators from the NRG Oncology
cooperative group will look at the relationship between ADT-RS scores and PAM50
subtypes in patients treated with first-line radiotherapy and hormones in patients from
completed randomized controlled trials.
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Our study did have some noteworthy limitations. First, the study was conducted on
retrospective cohorts of mostly Caucasians and any marginal estimates obtained in this study
may therefore be biased. Further characterization of ADT-RS in the African Americans is
needed. Care was taken in using the appropriate statistical methods to account for issues
introduced through reweighting and replication of retrospective observational data, but there
is no substitute for level 1 evidence. Second, given the retrospective nature of this study it is
uncertain whether patients discontinued treatment after a period of ADT. Validation in
cohorts from randomized clinical trials obtained either retrospectively or prospectively will
be important to validate this predictive gene signature. Moreover, the ADT-RS cut-off point
of 0.36 was originally obtained without regard to ADT response, but objectively derived by
median split so that bias may be reduced in the comparison of predictive performance with
that of Decipher and mCCP. This cut-off point will require further validation as a clinically
meaningful cut-off point useful for selection of a-ADT. As additional transcriptomic data
from larger datasets becomes available, it is possible that more specific signatures can be
developed using the same methodology. We acknowledge that the ADT-RS gene signature
derived from neuroendocrine genes does not encompass the complete spectrum of ADT
resistance mechanisms and there is potential for improvement with future investigations and
Clin Cancer Res. Author manuscript; available in PMC 2019 May 13.
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additional transcriptomic data. Currently, ongoing studies looking at ADT as first-line
therapy will be used to improve the current ADT-RS model. Finally, our findings also do not
directly apply to the metastatic prostate cancer or primary radiotherapy setting; however,
these are areas of active pursuit.
An ADT response signature validated as a predictive biomarker (as opposed to prognostic)
with a significant interaction term for predicting metastasis. Further validation studies on
random clinical trials are required to define the role of ADT-RS in predicting benefit or
response to early hormone therapy in men with high-risk prostate cancer after surgery. ADTRS may allow for identification of patients that may be optimal candidates for chemotherapy or trials of novel systemic agents.
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Refer to Web version on PubMed Central for supplementary material.
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Translational Relevance

Author Manuscript

Adjuvant ADT after surgery and/or radiation has demonstrated a survival benefit in
higher risk prostate cancer (PCa). Despite such benefits, ADT has been associated with
side effects and might not benefit every patient. Thus, identification of a subset of
patients who are unlikely to receive benefit from ADT is a step in the right direction.
Neuroendocrine (NE)PCa has higher rates of ADT resistance and is highly correlated
with castration-resistant disease. Stemming from this observation, we reasoned that a
score created from gene expression patterns of NEPCa may serve as an early marker of
androgen resistance for primary prostate tumors in the localized disease setting. Here, we
developed and validated a genomic signature for predicting ADT response after radical
prostatectomy using neuroendocrine and ADT resistance genes. This signature allows for
earlier identification of ADT-responsive prostate cancers that may be more optimal
candidates for multimodal systemic therapy or clinical trials of novel agents.
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Figure 1.

Study consort diagram describing the case-control training set (Mayo Clinic I) and three
validation sets from Mayo Clinic II (MC II) and John Hopkins Hospitals (JHU).
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Figure 2.

Frequency of patients across ADT-RS scores and category (low vs. high) within validation
set I (A), validation set II (B), and 1:1 matched validation set III (C).
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Figure 3.
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Cumulative incidence of metastasis given ADT and ADT-RS scores. Cumulative incidence
curves showing that among patients with low ADT-RS scores (A), incidence of metastasis is
not significantly different between treatment arms, and among patients with High ADT-RS
scores, a-ADT patients are at significantly reduced risk of metastasis compared with noADT patients (B). C, Bar plots illustrating the 10-year cumulative incidence of metastasis
rates for each ADT-RS by ADT treatment combination.
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Figure 4.
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Cumulative incidence of metastasis given ADT and prognostic signatures in the matched
validation set III. Cumulative incidence curves comparing a-ADT and no-ADT patients for
patients with low (A) and high Decipher, showing that patients in the a-ADT arm have lower
incidence of metastasis in high but not low Decipher (B). C, Bar plots illustrating the 10year cumulative incidence of metastasis rates for low and high Decipher (split by median
score) by ADT treatment combination. Cumulative incidence curves comparing a-ADT and
no-ADT patients for patients with low cell-cycle genes (D) and high cell-cycle genes score
(E), showing that patients in the a-ADT arm have lower incidence of metastasis in both low
and high cell-cycle genes. F, Bar plots illustrating the 10-year cumulative incidence of
metastasis rates for low and high cell-cycle genes (split by median score) by ADT treatment
combination.
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Table 1.

Author Manuscript

Demographic and clinical characteristics of eligible patients
Variables

Training set

Validation set I

Validation set II

Validation set III

Patients, n (%)

284 (100%)

232 (100%)

435 (100%)

612 (100%)

Median (range)

67 (48–78)

64 (46–78)

62 (38–78)

62 (46–78)

IQR (Q1–Q3)

62–70

58–69

57–66

58–67

Median (range)

14.2 (1.2–201)

9.4 (1.8–194)

9.4 (1.8–194)

9.5 (1.8–194)

IQR (Q1–Q3)

7.5–28.0

6.2–15.9

6.2–15.1

5.9–15.8

8(3%)

Patient age, y

Preoperative PSA (ng/mL)

Pathologic Gleason score, n (%)
≤6

18 (8%)

19 (4%)

29 (5%)

a

76 (33%)

141 (32%)

213 (35%)

a

41 (18%)

79 (18%)

93 (15%)

8

57 (20%)

39 (17%)

63 (14%)

76 (12%)

≥9

7 (3+4)

NA

Author Manuscript

7 (4+3)

NA

115 (40%)

58 (25%)

133 (31%)

201 (33%)

Extraprostatic extension, n (%)

208 (73%)

99 (43%)

251 (58%)

284 (46%)

SVI, n (%)

153 (54%)

80 (80%)

151 (35%)

367 (60%)

Positive surgical margins, n (%)

172 (61%)

133 (57%)

192 (44%)

371 (61%)

LNI, n (%)

72 (25%)

33 (14%)

84 (19%)

183 (30%)

Adjuvant radiotherapy, n (%)

43 (15%)

49 (21%)

49 (11%)

101 (17%)

Androgen deprivation therapy, n (%)

142 (50%)

102 (44%)

102 (23%)

306 (50%)

Median (range)

15.2 (5.9–21.9)

7.0 (0.0–11.6)

7.9 (0.0–19.0)

7.4 (0.2–18.0)

IQR (Q1–Q3)

13.0–18.2

4.9–9.1

5.2–10.1

5.2–9.4

Follow-up time for censored patients, y

Author Manuscript

a

Primary Gleason grade unavailable for Training set. A total of 104 patients (37%) had a Gleason score of 7.
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Table 2.

Author Manuscript

Results of Cox proportional hazards analysis of ADT-RS and clinicopathologic risk factors
UVA

MVA

Author Manuscript

Variables

HR (95% CI)

P

HR (95% CI)

P

Validation set I

Log2 pretreatment PSA

1.16 (0.91–1.48)

0.227

1.19 (0.91–1.57)

0.203

(Mayo Clinic MC II)

Pathologic Gleason ≥ 4+3

4.33 (2.27–8.25)

<0.001

3.57 (1.72–7.40)

0.001

Extraprostatic extension

2.88 (1.66–5.00)

<0.001

1.10 (0.53–2.28)

0.789

Seminal vesicle invasion

2.39 (1.39–4.12)

0.002

1.68 (0.84–3.34)

0.143

Positive surgical margins

1.05 (0.61–1.79)

0.868

1.47 (0.75–2.90)

0.260

Lymph node invasion

2.06 (1.02–4.14)

0.043

0.57 (0.23–1.43)

0.231

Adjuvant radiation therapy

1.83 (1.00–3.38)

0.052

0.98 (0.44–2.21)

0.966

ADT-RS

0.91 (0.35–2.34)

0.841

0.91 (0.34–2.39)

0.842

ADT

5.60 (2.94–10.65)

<0.001

3.93 (1.79–8.62)

0.001

Author Manuscript

ADT-RS:ADT interaction

0.20 (0.06–0.71)

0.013

0.18 (0.05–0.65)

0.009

Validation set II

Institution (ref: Hopkins)

0.67 (0.46–0.96)

0.031

0.42 (0.23–0.77)

0.005

(Mayo Clinic MC II + Hopkins JHU)

Log2 pretreatment PSA

1.17 (0.97–1.41)

0.097

1.14 (0.92–1.40)

0.240

Pathologic Gleason ≥ 4+3

4.91 (3.11–7.76)

<0.001

3.81 (2.32–6.24)

<0.001

Extraprostatic extension

3.27 (2.16–4.93)

<0.001

1.27 (0.75–2.13)

0.370

SVI

3.53 (2.41–5.18)

<0.001

2.57 (1.59–4.16)

<0.001

Positive surgical margins

1.26 (0.87–1.82)

0.220

1.86 (1.17–2.97)

0.008

LNI

3.71 (2.38–5.80)

<0.001

1.77 (1.01–3.08)

0.045

Adjuvant radiotherapy

1.35 (0.77–2.38)

0.290

0.86 (0.34–2.15)

0.746

ADT-RS

0.52 (0.33–0.81)

0.004

0.67 (0.41–1.09)

0.109

ADT

2.32 (1.45–3.72)

<0.001

1.78 (0.86–3.69)

0.121

ADT-RS:ADT interaction

0.34 (0.13–0.90)

0.031

0.25 (0.08–0.80)

0.019

NOTE: Boldface indicates statistical significance.
Abbreviations: ADT, androgen deprivation therapy; MVA, multivariable analysis; UVA, univariable analysis.
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